Published in Drug Week, April 2nd, 2004
Net sales for the year ended December 31, 2003, rose 103% to a record $45.50 million, from $22.38 million for the year ended December 31, 2002. Gross profit for 2003 increased 151% to $25.99 million, from $10.33 million for 2002.
Net income for 2003 improved to $11.22 million, or $0.44 per fully diluted share, compared with a net loss of $2.26 million, or $(0.10) per fully diluted share for 2002. SG&A expenses of $7.36 million in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.